Norfloxacin (MK-0366, AM-715): In vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing
- 1 June 1983
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 1 (2) , 165-172
- https://doi.org/10.1016/0732-8893(83)90047-0
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1982
- Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agentsInfection, 1982
- Sch 29482, a new oral penem: comparative in-vitro activity, -lactamase stability and inhibitionJournal of Antimicrobial Chemotherapy, 1982
- Multiple antibiotic resistance and capsular types of gentamicin-resistant Kiebsiella aerogenesJournal of Antimicrobial Chemotherapy, 1981
- Comparative Activities of AM-715 and Pipemidic and Nalidixic Acids Against Experimentally Induced Systemic and Urinary Tract InfectionsAntimicrobial Agents and Chemotherapy, 1981
- In Vitro Antibacterial Activity of AM-715, a New Nalidixic Acid AnalogAntimicrobial Agents and Chemotherapy, 1980
- Apparent absence of transferable resistance to nalidixic acid in pathogenic Gram-negative bacteriaJournal of Antimicrobial Chemotherapy, 1977
- In Vitro Antimicrobial Activity of Cinoxacin Against 2,968 Clinical Bacterial IsolatesAntimicrobial Agents and Chemotherapy, 1976
- Nalidixic Acid: an Antibacterial ParadoxAntimicrobial Agents and Chemotherapy, 1975
- Emergence of resistant organisms as a function of dose in oxolinic acid therapyThe Lancet Healthy Longevity, 1971